Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

68.59 -0.24 (-0.35%)
Streaming Delayed Price Updated: 3:56 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Why Arcus Biosciences' Big Reveal Wasn't Very Exciting
No news from Arcus Biosciences is bad news for the company and other industry heavyweights. 
Via The Motley Fool
Here's Why Arcus Biosciences Stock Is Rising Today
Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise. 
Via The Motley Fool
Arcus Biosciences Rockets, But Vague Update In Cancer Study Divides Analysts
Arcus Biosciences offered a vague update on its lung cancer regimens Wednesday, but RCUS stock rocketed on Thursday. 
Via Investor's Business Daily
Price to Earnings Ratio Insights for Gilead Sciences
Right now, Gilead Sciences Inc. (NASDAQ:GILD) share price is at $66.75, after a 0.45% decrease. Over the past month, the stock increased by 0.60%, but over the past... 
Via Benzinga
9 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
Gilead's Kite Pharma Collaborates With Shoreline Biosciences For Cell Therapies For Cancer Settings
Kite Pharma, a unit of Gilead Sciences Inc (NASDAQ: GILD) and Shoreline Biosciences Inc, has entered into a strategic partnership to develop novel cell... 
Via Benzinga
Should You Buy Biotech ETFs Now?
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and... 
Via Talk Markets
Why Jounce Therapeutics Bounced Higher Today
The company gets a regulatory nod that will put $25 million in its pocket. 
Via The Motley Fool
Exposures Product Safety
Jounce Therapeutics Stock Is Trading After $25M In Milestone Payment From Gilead
The FDA has signed off Jounce Therapeutics Inc's (NASDAQ: JNCE) Investigational New Drug (IND) application for JTX-1811, triggering a milestone payment of $25... 
Via Benzinga
Exposures Product Safety
Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains
Cocrystal Pharma Inc (NASDAQ: COCP) has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party... 
Via Benzinga
Exposures COVID-19
95 Firms Going Ex-Dividend Next Week, Including Merck, Gilead Sciences And Public Storage
Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend. 
Via Talk Markets
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
'Halftime Report' Traders Share Their Thoughts On Gilead, IBM And More
On CNBC's "Fast Money Halftime Report," Josh Brown said ICICI Bank Ltd (NYSE: IBN) looks like it's going higher. The long-term trend in the name looks great and... 
Via Benzinga
5 Top ETFs With Exposure To Biogen
Here is a look at five ETFs with large exposure to Biogen shares. 
Via Talk Markets
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
Exposures Product Safety
Gilead's Trodelvy New Subgroup Data Shows Benefit in Second-Line Breast Cancer Patients
Gilead Sciences Inc (NASDAQ: GILD) has announced new data from the Phase 3 ASCENT study evaluating Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory... 
Via Benzinga
NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure
NRx Pharmaceuticals (NASDAQ: NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19... 
Via Benzinga
Exposures COVID-19 Product Safety
Could Nano-X Be a Millionaire-Maker Stock?
Nano-X is not a safe investment -- it's a highly risky one. But its potential upside is incredible. 
Via The Motley Fool
Is It Too Late to Buy the Most Promising Pipeline in the Pharma Industry?
Fast-growing AstraZeneca might make an interesting addition to your portfolio. 
Via The Motley Fool
Can This Forgotten Coronavirus Stock Make You Rich?
Despite strong headwinds, there may be hope for this biotech. 
Via The Motley Fool
Exposures COVID-19
Market Briefing For Tuesday, May 25
Seasonal bias kicked-in, to the upside, ahead of Memorial Day, primarily it seems led by rotational rebounds in the usual suspects of momentum stocks, but also as Oil moved above 65 / bb,; suggesting... 
Via Talk Markets
NGM Stock Crashes As NASH Drug Joins Gilead, Genfit With Notable Flops
NGM Biopharmaceuticals joined a raft of biotech companies with a failed hepatitis treatment on Monday, leading NGM stock to crash. 
Via Investor's Business Daily
NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is a clinical-stage biopharma developing liver and metabolic disorders therapies. Its stock is down just 6.2% year-to-date... 
Via Benzinga
'Fast Money' Traders Weigh In On IBB And Gilead
On CNBC's "Fast Money," Tim Seymour spoke about a possible break out in iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). He said traders should be defensive in a high... 
Via Benzinga
How Small Biotech Allogene Is Making Waves For Gilead, Novartis
Allogene Therapeutics said its donor cell-derived cancer treatment was successful for six months, and ALLO stock popped Thursday. 
Via Investor's Business Daily
This Top Healthcare Dividend Stock Is a Bargain Right Now
Gilead Sciences' revenues are being boosted by its COVID-19 treatment, but it will still be a good investment in a post-pandemic world. 
Via The Motley Fool
Exposures COVID-19
2 High-Yield Dividend Stocks to Buy Now
They pay more than double what you'd earn with the average stock in the S&P 500. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
This High-Quality, Cheap Stock Is Rated A “Buy” And Looks 10% Undervalued
Morningstar rates GILD as a 4-star stock, with a fair value estimate of $81.00. CFRA rates GILD as a 3-star “HOLD”, with a 12-month target price of $66.00. 
Via Talk Markets
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.